Macular Degeneration Mouse Model of Wet-Type Age-Related Controls Choroidal Neovascularization in a CD 59 , a Complement Regulatory Protein ,

[1]  D. J. Unsworth,et al.  Complement deficiency and disease , 2008, Journal of Clinical Pathology.

[2]  H. Kaplan,et al.  Complement Activation via Alternative Pathway Is Critical in the Development of Laser-Induced Choroidal Neovascularization: Role of Factor B and Factor H1 , 2006, The Journal of Immunology.

[3]  H. Kaplan,et al.  Alcohol linked to enhanced angiogenesis in rat model of choroidal neovascularization , 2006, The FEBS journal.

[4]  R. T. Smith,et al.  Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration , 2006, Nature Genetics.

[5]  S. Barnum,et al.  Genetic deficiency of C3 as well as CNS-targeted expression of the complement inhibitor sCrry ameliorates experimental autoimmune uveoretinitis. , 2006, Experimental eye research.

[6]  John D Lambris,et al.  Drusen complement components C3a and C5a promote choroidal neovascularization. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Purushottam Jha,et al.  Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. , 2005, Journal of immunology.

[8]  J. Gilbert,et al.  Complement Factor H Variant Increases the Risk of Age-Related Macular Degeneration , 2005, Science.

[9]  A. Edwards,et al.  Complement Factor H Polymorphism and Age-Related Macular Degeneration , 2005, Science.

[10]  J. Ott,et al.  Complement Factor H Polymorphism in Age-Related Macular Degeneration , 2005, Science.

[11]  M. Mizuno,et al.  CD59a Is the Primary Regulator of Membrane Attack Complex Assembly in the Mouse1 , 2004, The Journal of Immunology.

[12]  M. Mizuno,et al.  Deletion of the gene encoding CD59a in mice increases disease severity in a murine model of rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[13]  M. Walport,et al.  CD59a deficiency exacerbates ischemia-reperfusion injury in mice. , 2004, The American journal of pathology.

[14]  B. Morgan,et al.  Complement therapeutics; history and current progress. , 2003, Molecular immunology.

[15]  M. Walport,et al.  CD59a deficiency exacerbates accelerated nephrotoxic nephritis in mice. , 2003, Journal of the American Society of Nephrology : JASN.

[16]  Masashi Mizuno,et al.  Characterization of the mouse analogues of CD59 using novel monoclonal antibodies: tissue distribution and functional comparison , 2003, Immunology.

[17]  H. Kaplan,et al.  Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  H. Kaplan,et al.  Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells , 2003, Nature Medicine.

[19]  M. Madaio,et al.  Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice. , 2002, The American journal of pathology.

[20]  J. Alexander,et al.  Transgenic Expression of a Soluble Complement Inhibitor Protects Against Renal Disease and Promotes Survival in MRL/lpr Mice1 , 2002, The Journal of Immunology.

[21]  L. V. Johnson,et al.  Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. , 2001, Experimental eye research.

[22]  M. Walport,et al.  Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria. , 2001, Blood.

[23]  W. Song,et al.  Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases. , 2001, International immunopharmacology.

[24]  H. Kaplan,et al.  Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59. , 2000, Investigative ophthalmology & visual science.

[25]  H. Kaplan,et al.  Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins. , 2000, Investigative ophthalmology & visual science.

[26]  P. Campochiaro,et al.  Retinal and choroidal neovascularization , 2000, Journal of cellular physiology.

[27]  M. Walport,et al.  C1q Deficiency and Autoimmunity: The Effects of Genetic Background on Disease Expression1 , 2000, The Journal of Immunology.

[28]  J. Halperin,et al.  Identification and Functional Characterization of a New Gene Encoding the Mouse Terminal Complement Inhibitor CD59 , 2000, The Journal of Immunology.

[29]  S. Russell,et al.  Drusen associated with aging and age‐related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  L. V. Johnson,et al.  A potential role for immune complex pathogenesis in drusen formation. , 2000, Experimental eye research.

[31]  A. Moore,et al.  Genetic susceptibility to age related macular degeneration , 2000, Journal of medical genetics.

[32]  B. Morgan,et al.  Soluble complement receptor one (sCR1) inhibits the development and progression of rat collagen‐induced arthritis , 2000, Clinical and experimental immunology.

[33]  N. Davoust,et al.  Central nervous system-targeted expression of the complement inhibitor sCrry prevents experimental allergic encephalomyelitis. , 1999, Journal of immunology.

[34]  L. Kobzik,et al.  Membrane attack complex of complement and neutrophils mediate the injury of acid aspiration. , 1999, Journal of applied physiology.

[35]  T. Takano,et al.  Complement C5b-9 induces receptor tyrosine kinase transactivation in glomerular epithelial cells. , 1999, The American journal of pathology.

[36]  J. Alexander,et al.  Transgenic Mice Overexpressing the Complement Inhibitor Crry as a Soluble Protein Are Protected from Antibody-induced Glomerular Injury , 1998, The Journal of experimental medicine.

[37]  E. Kremmer,et al.  Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. , 1998, Journal of immunology.

[38]  M. Seldin,et al.  Molecular cloning and chromosomal localization of the mouse decay-accelerating factor genes. Duplicated genes encode glycosylphosphatidylinositol-anchored and transmembrane forms. , 1995, Journal of immunology.

[39]  W. Couser,et al.  The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis. , 1995, Journal of the American Society of Nephrology : JASN.

[40]  D. Hourcade,et al.  Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein , 1995, The Journal of experimental medicine.

[41]  H. Lassmann,et al.  Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. , 1994, Journal of immunology.

[42]  J. Halperin,et al.  Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells , 1994, The Journal of experimental medicine.

[43]  J. Pepose,et al.  Differential expression of the complement regulatory proteins in the human eye. , 1993, Investigative ophthalmology & visual science.

[44]  J. Halperin,et al.  Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells. , 1993, The Journal of clinical investigation.

[45]  M. Frank,et al.  The role of complement in inflammation and phagocytosis. , 1991, Immunology today.

[46]  F. Ferris,et al.  Age-related macular degeneration and blindness due to neovascular maculopathy. , 1984, Archives of ophthalmology.

[47]  S. Ryan,et al.  Subretinal neovascularization. Natural history of an experimental model. , 1982, Archives of ophthalmology.

[48]  J. Alexander,et al.  Molecular characterization of rat Crry: widespread distribution of two alternative forms of Crry mRNA , 2004, Immunogenetics.

[49]  H. Lassmann,et al.  Deficiency of the complement regulator CD59a enhances disease severity, demyelination and axonal injury in murine acute experimental allergic encephalomyelitis , 2004, Laboratory Investigation.

[50]  A. Grumach,et al.  Involvement of C4 allotypes in the pathogenesis of human diseases. , 2004, Revista do Hospital das Clinicas.

[51]  A. Levine,et al.  Complement in Inflammatory Bowel Disease Sodium-Induced Colitis : Role for Increases Susceptibility to Dextran Sulfate Decay-Accelerating Factor Deficiency , 2004 .

[52]  Deeba Husain,et al.  Mechanisms of age-related macular degeneration. , 2002, Ophthalmology clinics of North America.

[53]  M. Nangaku,et al.  Glomerulonephritis Anti-Glomerular Basement Membrane Decay-Accelerating Factor Deficient Mice to Increased Susceptibility of , 2001 .

[54]  B. Morgan,et al.  Physiology and pathophysiology of complement: progress and trends. , 1995, Critical reviews in clinical laboratory sciences.

[55]  C. Parker,et al.  Membrane inhibitor of reactive lysis. , 1992, Current topics in microbiology and immunology.